A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Lymphoma, B-Cell · Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia · Waldenstrom Macroglobulinemia · Mantle Cell Lymphoma · Diffuse Large B Cell Lymphoma · Richter's Transformation · Follicular Lymphoma · Marginal Zone Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 190 (planned)
- Started
- Jun 26, 2017
- Main results expected
- Sep 17, 2027
- Fully finished
- Sep 17, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
Measured over: Cycle 1 (up to 28 days)
Phase 1: Number of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 86 months
Phase 1: Number of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to approximately 86 months
Phase 2: Expansion Cohorts A, B & C: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by the Investigator
Measured over: Up to approximately 64 months
Phase 2: Expansion Cohorts A, B, C: ORR per Lugano Classification as Assessed by the Investigator
Measured over: Up to approximately 64 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03162536 · record last updated 2026-06-12 · checked 2026-11-09 15:47 UTC